Researchers Identified Host Protein Facilitating Flu Replication
A specific human RNA helicase boosts viral polymerase activity, revealing how avian flu strains adapt to mammals.
Updated on Sept. 22, 2026 in Life Sciences
Scientists have identified DDX10 as a host factor that significantly enhances the replication of human-adapted influenza A viruses. This research-stage finding clarifies how avian-origin viruses gain the ability to replicate efficiently within human cells.
Why it matters
Understanding the host-pathogen interface is critical for mapping how zoonotic viruses jump species barriers. By isolating the specific mechanisms behind mammalian adaptation, researchers can better track the evolution of H1N1 and similar pathogens.
Researchers identified that DDX10 enhances H1N1 polymerase activity by interacting with two specific residues, 336 and 364, in the PB1 catalytic domain. Mutating these residues in avian H9N2 strains confers DDX10 responsiveness, while identical mutations in H1N1 abolish it.
The players
DDX10
A human DEAD-box RNA helicase protein that regulates RNA-based viral replication processes.
PB1 Polymerase
A core enzyme within the influenza virus that catalyzes the synthesis of viral RNA during replication.
The details
The study utilized a functional screen of 16 human DEAD-box RNA helicases—proteins that rearrange RNA structures—to determine how they influence viral machinery. The team found that DDX10 binds more effectively to the PB1 polymerase of human-adapted strains than to those from avian sources. This interaction is mediated by the PB1 catalytic domain, where positions 336 and 364 act as the structural triggers for viral replication efficiency.
Timeline
September 22, 2026: The research findings were published.
The Tech Race
This study sits within the ongoing effort to map the host factors that dictate cross-species viral compatibility. It provides a precise structural target that contrasts with broader, less granular genomic surveillance programs.
This research provides a fundamental mechanism for future antiviral development targeting host-pathogen interactions. There are no immediate clinical products available, as the findings remain in the foundational research stage.
The takeaway
The identification of these two critical residues in the PB1 domain marks a transition from observing viral adaptation to understanding its precise mechanics. Future studies should monitor whether novel zoonotic strains acquire the 336 or 364 residue mutations that allow them to exploit human DDX10.
Further reading
For broader context on viral adaptation research, visit the Life Sciences section.
Source note: This article includes information reported by Journal of Virology.
